Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
1 clinical trials · Condition
◉ Watch Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
| Record | Firm | Date |
|---|---|---|
| A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) (NCT04395456) | Amyndas Pharmaceuticals S.A. | 2021-09-01 |
Track Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19) automatically
Every clearance here is in the API, with alerts when new ones post.